Premium
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte‐predominant H odgkin lymphoma
Author(s) -
Porrata Luis F.,
Ristow Kay,
Habermann Thomas M.,
Witzig Thomas E.,
Colgan Joseph P.,
Inwards David J.,
Ansell Stephen M.,
Micallef Iva.,
Johnston Patrick B.,
Nowakowski Grzegorz S.,
Thompson Carrie,
Markovic Svetomir N.
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09067.x
Subject(s) - lymphocyte , monocyte , lymphoma , peripheral blood , medicine , immunology , peripheral blood lymphocyte , hodgkin lymphoma , pathology
Summary The pathological background in nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) consists of lymphocytes and histocytes. This study analysed the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis ( ALC / AMC ‐ DX ) on the impact of survival in NLPHL . One hundred and three consecutive NLPHL patients that were followed at M ayo C linic from 1974 to 2010 were included in the study. Receiver operating characteristic and area under the curve were used for ALC / AMC ‐ DX cut‐off value analysis and proportional‐hazards models were used to compare survival based on the ALC / AMC ‐ DX ratio. With a median follow‐up of 8·9 years (range: 0·3–31 years), an ALC / AMC ‐ DX ≥2·1 was the best cut‐off value for survival with an area under the curve of 0·82, a sensitivity of 70% and specificity of 84%. After adjusting for the I nternational P rognostic S core ( IPS ), ALC / AMC ‐ DX remained an independent prognostic factor for overall survival [ H azard R atio ( HR ), 0·33, 95% confidence interval ( CI ), 0·15–0·71%, P < 0·004]; lymphoma‐specific survival ( HR , 0·05; 95% CI , 0·01–0·68%, P < 0·002); progression‐free survival ( HR , 0·30; 95% CI , 0·14–0·60%, P < 0·006), and time to progression ( HR , 0·06, 95% CI , 0·04–0·30%, P < 0·004). ALC / AMC ‐ DX is a low cost, already standarized, biomarker to predict clinical outcomes in NLPHL .